Brings assets under management to $1.2 billion
CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture capital firm, announced today the single close of Clarus Lifesciences II, L.P. ("Clarus II"), a $660 million fund in Limited Partner commitments. This is the second investment fund formed and managed by Clarus Ventures, since the firm was established in 2005.
Clarus II will invest $20-60 million in biotechnology, specialty pharmaceutical and medical technology companies that are developing innovative products for the treatment of human diseases. The firm's first fund has committed 90 percent of its proceeds to date.
"We have effectively completed the deployment of our first fund and built a diversified portfolio of exciting companies," said Robert Liptak, a Clarus Ventures Managing Director. "These include companies with strong growth in revenue and profitability such as Globus Medical; products near commercialization such as Sientra, Pelikan, Oxford and Zogenix; and those with breakthrough products and technologies such as Aerovance, Centaurus, CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation. We plan to follow a similar investment strategy for Clarus II. With the diversity and depth of our team we believe we can leverage our experience to identify and help grow leading companies in the life sciences field."
The Limited Partner base for Clarus II was effectively the same as in Clarus I. A small, select group of new high-quality investors who knew the firm well also participated.
The Clarus Ventures team is led by Nicholas Galakatos, Dennis Henner,
Jeffrey Leiden, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt
Wheeler, an established group of investment professionals with deep and
complementary backgrounds within the life sciences industry. The team
uniquely balances broad investing expertise wi
|SOURCE Clarus Ventures, LLC|
Copyright©2008 PR Newswire.
All rights reserved